Approval of emergency use of another drug in the treatment of corona
DCGI i.e. Drugs Controller General of India has approved the emergency use of another drug in the treatment of Corona. It has been jointly prepared by DRDO’s Institute of Nuclear Medicine and Allied Sciences INMAS and Hyderabad Center for Cellular and Molecular Biology CCMB.
This drug is named 2-deoxy-D-glucose (2-DG). The responsibility of manufacturing it has been given to Dr Reddy Laboratories based in Hyderabad.
According to the report by Manjeet Negi of India Today, clinical trials of the drug have been successful. It is claimed that rapid recovery was seen in the patients on whom it was used.
Also, the dependence of oxygen on patients was reduced. It is also claimed that the corona report of patients using this drug is getting negative compared to the rest of the patients.
Drugs Controller General of India approves anti-COVID drug developed by @DRDO_India for emergency use
Clinical trial results have shown that this molecule helps in faster recovery of hospitalized patients and reduces supplemental oxygen dependence
Read: https://t.co/L2ixpQUPlx pic.twitter.com/5qohE4jGtx
— PIB India (@PIB_India) May 8, 2021
In April 2020, DRDO scientists experimented on this drug. In the experiment, it was found that this drug helps in preventing the coronavirus. Based on this, DCGI had approved to conduct Phase-II trials in May 2020.
How was the trial?
This drug has been tried in hospitals across the country. Phase 6 trials of Phase-IIa and Phase-IIb trials were conducted in 11 hospitals. 110 patients were included in this. The trial was conducted between May 2020 to October 2020. Patients who were tried on this drug were cured 2.5 days earlier than the rest of the patients.
Phase-III trials were conducted in 27 hospitals across the country between December 2020 to March 2021. This time 220 patients were included in it. These trials were conducted in Delhi, UP, Bengal, Gujarat, Rajasthan, Maharashtra, Andhra, Telangana, Karnataka and Tamil Nadu.
Out of those who were given 2-DG medicine, 42% of the patients had oxygen dependence on the third day.
However, only 31% of patients who were not given medication lost their dependence on oxygen. That is, the drug also reduced the need for oxygen. A good thing is also that the same trend was seen in the elderly above 65 years.
According to the report, this drug comes in powder form. Used by dissolving in water. The drug accumulates in infected cells and prevents the virus from growing by producing viral synthesis and energy.